Firefly Neuroscience Inc
fireflyneuro.comFirefly Neuroscience Inc (NASDAQ: AIFF) is a medical device company that develops EEG-based neurotechnology for cognitive assessment. Its primary product, the Evoke System, captures resting-state EEG and Event-Related Potentials across 19 electrode channels plus an integrated heart rate variability sensor, enabling measurement of up to 20 distinct cognitive functional measures per session, including attention, working memory, response inhibition, and executive function (per the 10-K filed 2026-03-31). The company generates revenue from the commercialization of this device and its analytics engine, which compares patient electrophysiological data against a proprietary reference database. The company operates in the medical device industry, which it describes as intensely competitive and subject to rapid change. Firefly Neuroscience maintains operations in both the United States and Israel, and its combined technology and dataset have been the subject of more than 20 peer-reviewed publications in indexed scientific journals as of the 2026-03-31 filing.
Products & Services
Evoke System: a 19-channel EEG hardware device with integrated HRV sensor that captures resting-state EEG and Event-Related Potentials, supporting assessment of up to 20 cognitive functional measures per session. Analytics engine that compares patient data against a proprietary electrophysiological reference database. Applications span ADHD, major depressive disorder, traumatic brain injury, early Parkinson's disease detection, and neuropharmacology trials (per 10-K filed 2026-03-31).
Revenue Model
Device-based revenue from the Evoke System and associated analytics engine. The company has also raised capital through an at-the-money equity offering via a sales agent (Konik), with a 2.0% commission on gross proceeds, and a March 2026 units offering at $1.50 per unit to accredited investors (per 10-K filed 2026-03-31).
Customers & Markets
Healthcare providers and clinical settings requiring objective cognitive assessment. End markets include neurology, psychiatry, and neuropharmacology clinical trials. The filing references healthcare providers and third-party payers, including commercial insurers, as part of the reimbursement environment (per 10-K filed 2026-03-31).
Geographic Exposure
United States and Israel. The company discloses Israeli operations with employees subject to Israel Defense Force military service obligations. The filing notes exposure to geopolitical conflict in the region and related sanctions, export control, and regulatory risk (per 10-K filed 2026-03-31).
Financial Snapshot
Loading...
